APA (7th ed.) Citation

M, M., C, S., C, D., F, M., E, B., F, B., . . . M, B. (2023). Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 77(2), 280. https://doi.org/10.1093/cid/ciad181

Chicago Style (17th ed.) Citation

M, Mikulska, et al. "Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 77, no. 2 (2023): 280. https://doi.org/10.1093/cid/ciad181.

MLA (9th ed.) Citation

M, Mikulska, et al. "Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 77, no. 2, 2023, p. 280, https://doi.org/10.1093/cid/ciad181.